Purpura is a hemorrhagic disease characterized by the presence of disappearing hemorrhages on the skin and mucous membranes, which is caused by impaired vascular permeability or disorders in the blood coagulation system. Purpura is classified into several types, including thrombocytopenic purpura, including immune and non-immune, as well as microvascular and vasculitic forms. This disease can manifest itself in various clinical forms, ranging from mild cases with small bruises to severe conditions accompanied by profuse bleeding. Patient-oriented assessment, diagnosis and treatment of purpura require a thorough examination of the anamnesis, clinical symptoms and laboratory data.
History of the disease and interesting historical facts
The history of purpura goes back to ancient times, when similar symptoms could be observed, but had no clear clinical description. The first mentions of purpura can be found in the works of Hippocrates and Galen, who described skin hemorrhages. In the Middle Ages, important steps in understanding diseases of the circulatory system were made thanks to the work of Arab doctors. In the 19th century, with the development of hematology and the description of various types of vascular reactions and blood clotting, the term "purpura" began to be associated with specific pathologies. In the 1900s, many causes and forms of this condition became known, including hereditary and acquired. Modern research opens new horizons in the etiology, pathogenesis and treatment of purpura, which allows us to improve the quality of life of patients.
Epidemiology
The prevalence of purpura varies depending on the form of the disease. According to international studies, thrombocytopenic purpura has an estimated prevalence of 1.6 to 3 people per 100,000 population, while vasculitic forms are less common. Certain population groups, such as children and young women, are more susceptible to the risk of developing such a pathology, especially in cases associated with infectious and autoimmune processes. Purpura can occur against the background of both local and systemic diseases, which requires a more detailed study of the sources and risk factors.
Genetic predisposition to this disease
Genetic predisposition plays a significant role in the pathogenesis of some forms of purpura, especially in cases associated with thrombocytopenic purpura. Mutations in genes responsible for coagulation factors and platelet function have been described in the literature. For example, a mutation in the GP1BA gene encoding glycoprotein Ib alpha is associated with general thrombocytopenic purpura. Also, certain polymorphisms in genes such as FGFR2, CASP8, and IL10 have been associated with an increased risk of vasculitis. Modern genes, mutations, and polymorphisms continue to be actively studied in the context of genetic diagnostics to clarify risks and treatment methods.
Risk factors for the development of this disease
There are a number of factors that contribute to the development of purpura, among which the following should be highlighted:
- Infectious processes such as viral diseases (eg, viral hepatitis, HIV)
- Immune disorders, including systemic diseases (eg, systemic lupus erythematosus)
- Incorrect use of medications, including anticoagulants and antibiotics
- Environmental factors including chemicals and toxins
- Trauma and surgical procedures that result in damage to the vascular walls
These factors can influence both the development of primary forms of purpura and contribute to the activation of existing diseases.
Diagnosis of this disease
Diagnosis of purpura requires a multi-step approach, covering clinical, laboratory and instrumental methods. The main symptoms include:
- Erythema and petechiae on the skin
- Hemorrhages on the mucous membranes
- Fatigue and weakness syndromes
- Joint and muscle pain
Laboratory tests play a key role in diagnosis, including:
- Complete blood count with platelet count
- Checking liver and kidney function
- Analysis for the presence of antiphospholipid antibodies and other markers of autoimmune diseases
Radiological studies are sometimes used to exclude other pathologies. An important step is differential diagnostics, which allows distinguishing purpura from other types of hemorrhagic diseases, such as hemophilia and vasculitis in the thrombus formation system.
Treatment
Treatment of purpura depends on its form and cause, which requires an individualized approach. In general, therapy may include:
- General treatment: Bed rest, saturating the body with vitamins and healthy food
- Pharmacological treatment: Corticosteroids to suppress inflammation and immunosuppressants
- Surgical treatment: If necessary, splenectomy or other surgical interventions may be performed
- Other types of treatment: Plasmapheresis methods, as well as the use of immunostimulants, may be recommended in certain cases.
The choice of therapy method is based on the severity of the patient's condition, the presence of concomitant diseases and the general prognosis.
List of medications used to treat this disease
The main drugs used to treat purpura include:
- Corticosteroids: prednisone, methylprednisolone
- Immunosuppressants: azathioprine, cyclophosphamide
- Hemostatic agents: captopril, transexamic acid
- Antibodies to CD20: rituximab
- Systemic antihistamines: diphenhydramine, loratadine
Well-chosen therapy significantly improves the prognosis of patients.
Disease monitoring
Monitoring patients with purpura involves regular check-ups and follow-up tests to assess the progress of the disease. This may include:
- Regular blood tests to assess platelet levels
- Clinical testing for new symptoms
- Examinations for functional disorders of organs
Prognosis may vary from favorable to unfavorable, depending on the type of purpura, associated diseases, and the adequacy of treatment. Possible complications include repeated bleeding episodes and the development of chronic forms of the disease.
Age-related features of the disease
Purpura can manifest itself in various age categories, but its clinical picture and course vary somewhat depending on age. In children, acute thrombocytopenic forms are often observed, while in the elderly, purpura can be associated with systemic diseases. It is also worth noting that women, especially those of reproductive age, have an increased risk of developing vasculitis, which necessitates careful monitoring of the condition.
Questions and Answers
- What is purpura? Purpura is a disease characterized by the appearance of subcutaneous hemorrhages caused by impaired vascular permeability or hemostasis disorders.
- What are the main types of purpura? There are different types of purpura, including thrombocytopenic, vasculitic, and microvascular purpura.
- How is purpura diagnosed? Diagnostics includes a general blood test, laboratory tests and instrumental examination methods to exclude other diseases.
- Is it possible to treat purpura on your own? No, treatment of purpura requires mandatory medical supervision and an individual approach to therapy.
- What is the prognosis for purpura? The prognosis depends on the type of purpura, its cause and the adequacy of the treatment, with the possibility of significant improvement with a comprehensive approach.
